AKEEGA niraparib and abiraterone acetate
Drug Class
PARP inhibitor and CYP17 inhibitor fixed-dose combinationPARP抑制剂与CYP17抑制剂固定剂量复方制剂
Mechanism
Niraparib inhibits PARP1/2-mediated DNA repair while abiraterone blocks CYP17-mediated androgen synthesis, synergistically targeting tumor cell growth in BRCA-mutated prostate cancer.尼拉帕尼抑制PARP1/2介导的DNA单链损伤修复，而醋酸阿比特龙阻断CYP17酶介导的雄激素生物合成。两者联合作用，双重打击BRCA突变前列腺癌中的生存信号。
Approved Indication
Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, and BRCA2-mutated metastatic castration-sensitive prostate cancer, per its FDA approval.根据美国FDA批准，适用于携带BRCA基因突变的转移性去势抵抗性前列腺癌（mCRPC），以及携带BRCA2基因突变的转移性去势敏感性前列腺癌（mCSPC）。
What This Means For Patients
Akeega is a fixed-dose combination tablet of a PARP inhibitor (niraparib) and a hormone therapy (abiraterone) used to treat advanced prostate cancers harboring BRCA gene mutations. By blocking both DNA repair and hormone production, it provides a dual-action therapeutic approach available in Lecheng.Akeega是一种由PARP抑制剂（尼拉帕尼）和内分泌药物（阿比特龙）组成的固定剂量复合制剂，用于治疗携带BRCA突变的晚期前列腺癌。它通过双重阻断DNA修复和雄激素合成发挥治疗作用，可在博鳌乐城先行区获取。
Regulatory Approvals
- FDA — approved (2023) — source
Pivotal Clinical Evidence
- MAGNITUDE — Chi et al., J Clin Oncol 2023 (NCT03748641) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.